Aclaris To Share New Clinical Data For Two Key Immunology Programs Today

April 28, 2026 — 03:22 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) is preparing to release new clinical results for two of its lead immuno-inflammatory drug candidates, marking an important update in the company's biologic and oral inhibitor pipeline.

The company announced that it will provide full results from its Phase 1a single-and multiple-ascending-dose study of ATI-052- its anti-TSLP/IL-4R bispecific antibody- along with the lead indication selection for ATI-2138, an ITK/JAK3 inhibitor. Both updates will be shared before the U.S. financial markets open on April 28, 2026, at 8:30 AM EST.

ACRS has traded between $1.16 and $4.89 over the past year. The stock closed Monday's trading at $4.41, up 2.56%. During overnight trading, the stock traded at $4.55, up 3.17%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Aclaris To Share New Clinical Data For Two Key Immunology Programs Today

Tags

Latest Articles